Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms
A leading strategy for developing a prophylactic HIV-1 vaccine is the elicitation of antibodies that can neutralize a large fraction of circulating HIV-1 variants. However, a major challenge that has limited the effectiveness of current vaccine candidates is the extensive global diversity of the HIV...
Main Authors: | Amyn A. Murji, Juliana S. Qin, Tandile Hermanus, Lynn Morris, Ivelin S. Georgiev |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/7/1296 |
Similar Items
-
Multi-Substituted Quinolines as HIV-1 Integrase Allosteric Inhibitors
by: Long Phi Dinh, et al.
Published: (2022-07-01) -
Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region
by: Wenqi Tang, et al.
Published: (2023-03-01) -
A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target
by: Emma Parker Miller, et al.
Published: (2021-09-01) -
Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits
by: Nancy L. Tumba, et al.
Published: (2022-12-01) -
Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity
by: Yuanyuan Hu, et al.
Published: (2021-03-01)